|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105.8 SEK | +2.03% |
|
+3.18% | -18.41% |
Calliditas Therapeutics AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 1,206.89 million compared to SEK 802.88 million a year ago. Net loss was SEK 466.19 million compared to SEK 412.27 million a year ago.
Basic loss per share from continuing operations was SEK 8.69 compared to SEK 7.78 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.41% | 508M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
CALLIDITAS THERAPEUTICS AB 
